RespireRx Pharmaceuticals Inc.OTCQB
Thu, Sep. 1, 4:47 PM
Dec. 17, 2015, 11:48 AM| Dec. 17, 2015, 11:48 AM | 2 Comments
Jul. 1, 2014, 11:09 AM
- Cortex Pharmaceuticals (CORX +8.5%) enters into a license agreement with the University of Illinois for the exclusive rights to patents covering the use of cannabinoids for the treatment of sleep-related breathing disorders. The company is currently developing the cannabinoid dronabinol (D9-tetrahydrocannabinol) for the treatment of obstructive sleep apnea (OSA).
- Dronabinol is an FDA-approved generic drug indicated for AIDS-related anorexia and chemotherapy-induced emesis. The sleep apnea indication is an expansion of its label that will require the submission of a supplemental new drug application (sNDA).